Intense pulsed light-based treatment for the improvement of symptoms in glaucoma patients treated with hypotensive eye drops
Open Access
- 1 April 2022
- journal article
- research article
- Published by Springer Nature in Eye and Vision
- Vol. 9 (1) , 1-10
Abstract
Background: Ocular surface disease in glaucoma patients is a significant ocular co-morbidity that can affect 40% to 59% of these patients worldwide. The current study was aimed at evaluating the potential clinical benefit of an intense pulsed light (IPL)-based treatment in glaucomatous patients with ocular surface disease due to prolonged hypotensive eyedrop treatments. To our knowledge, this is the first series analyzing the therapeutic effect of this treatment option in this type of patients. Methods: This non-comparative prospective case series study enrolled a total of 30 glaucoma patients ranging in age from 57 to 94 years old and treated with hypotensive eyedrops for years with dry eye symptomatology. All patients received four sessions of IPL treatment using the Optima IPL system (Lumenis, Yokneam, Israel) adjusted to the official optimized Lumenis setting. Changes in symptomatology, corneal staining, conjunctival hyperemia, non-invasive break-up time (NIBUT), tear osmolarity, tear meniscus height (TMH), meiboscore and meibomian gland expressibility was analyzed after treatment. Results: Statistically significant reductions were observed after IPL treatment in the symptomatology scores measured with different questionnaires [ocular surface disease index (OSDI), standard patient evaluation of eye dryness (SPEED) and symptom assessment questionnaire in dry eye (SANDE)] as well as with the visual analogue scale (P < 0.001). Mean change in OSDI was − 15.0 ± 11.3. A significant reduction was found after treatment in the corneal staining score (P < 0.001). A significant reduction was found in tear film meniscus height (P = 0.012), as well as in tear film osmolarity (P = 0.001). A significant reduction was also found in meibomian gland expressibility (P = 0.003), changing the percentage of grade 3 eyes from 44.4% before IPL to 17.2% after treatment. Conclusions: IPL therapy combined with meibomian gland expression (MGX) seems to be an effective option to improve symptomatology in glaucomatous patients with ocular surface disease due to prolonged hypotensive eyedrop treatments, with an additional improvement in clinical signs, such as tear osmolarity and corneal staining.Keywords
This publication has 47 references indexed in Scilit:
- Dry eye specific quality of life in veterans using glaucoma dropsContact Lens and Anterior Eye, 2015
- Prospective Trial of Intense Pulsed Light for the Treatment of Meibomian Gland DysfunctionInvestigative Ophthalmology & Visual Science, 2015
- Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acidsClinical Interventions in Aging, 2013
- Assessment of Tear Film Stability in Dry Eye With a Newly Developed KeratographCornea, 2013
- Comparison of the Long-Term Effects of Various Topical Antiglaucoma Medications on Meibomian GlandsCornea, 2012
- A New System, the LipiFlow, for the Treatment of Meibomian Gland DysfunctionCornea, 2012
- Effects of long-term topical anti-glaucoma medications on meibomian glandsGraefe's Archive for Clinical and Experimental Ophthalmology, 2012
- Noncontact Infrared Meibography to Document Age-Related Changes of the Meibomian Glands in a Normal PopulationOphthalmology, 2008
- The validity and practicality of sun-reactive skin types I through VIArchives of Dermatology, 1988
- The Validity and Practicality of Sun-Reactive Skin Types I Through VIArchives of Dermatology, 1988